In India, Johnson & Johnson’s single-dose COVID-19 vaccination has been approved for emergency use.

Johnson & Johnson’s single-dose COVID-19 vaccination has been approved for Emergency Use Authorisation (EUA) in India, according to Union Health Minister Mansukh Mandaviya on Saturday (August 7, 2021). Mandaviya said on his official Twitter account that India had ‘increased its vaccine basket.’

“Johnson and Johnson’s single-dose COVID-19 vaccine has been approved for Emergency Use in India,” the Union Health Minister tweeted. “India now has 5 EUA vaccines, which will further strengthen our nation’s joint fight against COVID-19.”

According to a Johnson & Johnson India spokeswoman, the American multinational corporation applied to the government of India for EUA of its single-dose COVID-19 vaccine on August 5, 2021. The vaccine will be brought to India through a supply agreement with vaccine maker Biological E Ltd, according to a statement from the pharma company. The EUA submission is based on topline efficacy and safety data from the Phase 3 clinical trial ENSEMBLE, which demonstrated that their single-shot vaccine was 85% effective in preventing severe disease across all regions studied.

Beginning 28 days after vaccination, the Phase 3 clinical trial also demonstrated protection against COVID-19-related hospitalization and death.

The World Health Organization (WHO) designated the Johnson & Johnson (J&J)/Janssen vaccine for emergency use on March 12, this year, and the vaccine has ALSO been authorized for use in Europe, the United States, and other nations.

It should be mentioned that AstraZeneca (Covishield), Bharat Biotech (Covaxin), Russia’s Gamaleya Institute (Sputnik), and Moderna have all been licensed for usage in India.

A day after India’s cumulative immunization coverage surpassed 50 crores, Johnson & Johnson’s single-dose COVID-19 vaccine got Emergency Use Authorization. In response to the success, Prime Minister Narendra Modi stated on Friday that India’s war against COVID-19 had “got a great boost.”

Back to top button
Close
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker